BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37855927)

  • 21. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour markers are poor predictors for relapse or progression in neuroblastoma.
    Simon T; Hero B; Hunneman DH; Berthold F
    Eur J Cancer; 2003 Sep; 39(13):1899-903. PubMed ID: 12932669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
    Whittle SB; Smith V; Silverstein A; Parmeter M; Minard CG; Bernhardt MB; Zage PE; Venkatramani R; Nuchtern JG; Heczey A; Russell HV; Shohet JM; Foster JH
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28417. PubMed ID: 32729196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and risk factors of 47 cases with ruptured neuroblastoma in children.
    Qin H; Yang S; Cai S; Ren Q; Han W; Yang W; Cheng H; Ma X; Wang H
    BMC Cancer; 2020 Mar; 20(1):243. PubMed ID: 32293329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study.
    Sung KW; Son MH; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ; Lee SK; Choi YS; Lim DH; Kim JS; Kim DW
    Bone Marrow Transplant; 2013 Jan; 48(1):68-73. PubMed ID: 22635247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pre-surgical factors that determine the decision to proceed to resection in children diagnosed with high-risk neuroblastoma in a resource limited setting.
    van Heerden J; Kruger M; Esterhuizen TM; van Zyl A; Hendricks M; Cox S; Mangray H; Poole J; Naidu G; Büchner A; de Villiers M; du Plessis J; van Emmenes B; Matthews E; Manickchund Y; Harrison DS
    Pediatr Hematol Oncol; 2023 Apr; 40(3):242-257. PubMed ID: 36271813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification.
    Huang C; Jiang S; Yang J; Liao X; Li Y; Li S
    Medicine (Baltimore); 2020 Jun; 99(25):e20853. PubMed ID: 32569234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
    Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
    J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
    Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
    Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
    Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.
    Kushner BH; Heller G; Kramer K; Cheung NK
    Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term follow-ups of comprehensive therapies for stage 4 neuroblastoma].
    Zhang A; Pan C; Ye Q; Zhou M; Chen J; Luo C; Wang J; Tang Y; Xue H; Shen S; Tang J
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1547-52. PubMed ID: 25146742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
    Liao R; Sun XF; Zhen ZZ; Huang DS
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):735-740. PubMed ID: 30293276
    [No Abstract]   [Full Text] [Related]  

  • 37. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.
    Man S; Yan J; Li J; Cao Y; Hu J; Ma W; Liu J; Zhao Q
    Int J Med Sci; 2021; 18(8):1857-1865. PubMed ID: 33746603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review.
    Kramer K; Kushner B; Heller G; Cheung NK
    Cancer; 2001 Apr; 91(8):1510-9. PubMed ID: 11301399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
    Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
    Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
    Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
    J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.